Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Technology imitating life

23.02.2006


Scientists from Leicester have discovered a radical new approach to making artificial platelets to help stop bleeding in patients who have too few platelets of their own. This invention could be a major breakthrough for cancer patients suffering from severe or life threatening bleeding.



The development of this highly innovative product has been made possible thanks to a major funding round of £3.1m led by Quester, including investment from NESTA (the National Endowment for Science, Technology and the Arts), and the East Midlands Regional Venture Capitalist Fund.

As well as providing money in this funding round, NESTA has played an important role in providing vital seed finance, bridging the gap between the two rounds.


Platelets are blood cells, essential for the blood to clot. When patients suffer from platelet deficiency, blood clots cannot form properly and this can lead to life threatening bleeding. This is a particularly serious problem for patients with leukaemia and those receiving cancer therapy.

The development of the Haemostatix artificial platelets - Haemoplax - has been driven by an urgent need to find a more cost effective, safer, virus-free alternative to platelet transfusion.

The transfusion of platelets prepared from blood donations by Blood Transfusion Services is currently the only available treatment. One big drawback of this method is the potential for passing on infectious agents from donors to recipients, and recently, concerns about the potential risk of transmission of CJD (human BSE) are threatening the supply of platelets for transfusion. Platelets are also expensive to produce, have a shelf life of only five days, and need to be screened to remove the risk of transmission of blood-borne viruses that cause hepatitis and HIV.

Mark White, NESTA Invention and Innovation Director, said: “NESTA is well placed to identify innovative companies at the earliest stage of development and we are delighted to now have Quester and the East Midlands Regional Venture Capital Fund on board as co-investors. They have recognised, along with us, that Haemostatix is a classic illustration of a British firm which is successfully exploiting world-class science.”

Haemostatix, a spin-out from Leicester University, was founded in 2003 by Sarah Middleton (CEO) and Professor Alison Goodall (CSO) in conjunction with the University of Leicester which played a crucial supporting role in the company’s early stages.

Joseph Meaney | alfa
Further information:
http://www.nesta.org.uk

More articles from Life Sciences:

nachricht Topologische Quantenchemie
21.07.2017 | Max-Planck-Institut für Chemische Physik fester Stoffe

nachricht Topological Quantum Chemistry
21.07.2017 | Max-Planck-Institut für Chemische Physik fester Stoffe

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

Im Focus: On the way to a biological alternative

A bacterial enzyme enables reactions that open up alternatives to key industrial chemical processes

The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....

Im Focus: The 1 trillion tonne iceberg

Larsen C Ice Shelf rift finally breaks through

A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...

Im Focus: Laser-cooled ions contribute to better understanding of friction

Physics supports biology: Researchers from PTB have developed a model system to investigate friction phenomena with atomic precision

Friction: what you want from car brakes, otherwise rather a nuisance. In any case, it is useful to know as precisely as possible how friction phenomena arise –...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Closing the Sustainability Circle: Protection of Food with Biobased Materials

21.07.2017 | Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

 
Latest News

NASA looks to solar eclipse to help understand Earth's energy system

21.07.2017 | Earth Sciences

Stanford researchers develop a new type of soft, growing robot

21.07.2017 | Power and Electrical Engineering

Vortex photons from electrons in circular motion

21.07.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>